Adaptimmune Therapeutics (ADAP) Plans Offering of ADSs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Adaptimmune Therapeutics (ADAP) Prices 21 Million Offering at $4/ADS
January 22, 2020 8:49 AM ESTAdaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (ADSs) at a price to the public of $4.00 per ADS. In connection with the offering, Adaptimmune... More
